Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Aug 14, 2024

SELL
$0.55 - $2.89 $88,341 - $464,194
-160,621 Closed
0 $0
Q2 2023

Aug 14, 2024

BUY
$0.78 - $1.01 $205 - $265
263 Added 0.16%
160,621 $132 Million
Q1 2023

Aug 14, 2024

SELL
$0.72 - $1.12 $15,944 - $24,802
-22,145 Reduced 12.13%
160,358 $129 Million
Q4 2022

Aug 14, 2024

SELL
$0.83 - $8.04 $1,792 - $17,366
-2,160 Reduced 1.17%
182,503 $162 Million
Q3 2022

Aug 14, 2024

SELL
$1.98 - $2.42 $3,960 - $4,840
-2,000 Reduced 1.07%
184,663 $434 Million
Q2 2022

Aug 14, 2024

BUY
$2.21 - $2.7 $9,724 - $11,880
4,400 Added 2.41%
186,663 $416 Million
Q1 2022

Aug 14, 2024

BUY
$2.37 - $3.24 $431,963 - $590,532
182,263 New
182,263 $433 Million
Q4 2021

Aug 30, 2024

SELL
$2.92 - $3.76 $61,471 - $79,155
-21,052 Reduced 9.7%
195,951 $590 Million
Q3 2021

Aug 30, 2024

BUY
$3.28 - $4.07 $1,600 - $1,986
488 Added 0.23%
217,003 $808 Million
Q2 2021

Aug 30, 2024

BUY
$3.43 - $3.96 $742,646 - $857,399
216,515 New
216,515 $829 Million
Q1 2021

Aug 30, 2024

BUY
$2.2 - $3.94 $49,940 - $89,438
22,700 Added 11.02%
228,765 $879 Million
Q4 2020

Aug 30, 2024

SELL
$1.91 - $2.5 $46,709 - $61,137
-24,455 Reduced 10.61%
206,065 $509 Million
Q3 2020

Aug 30, 2024

SELL
$1.96 - $2.92 $6,119 - $9,116
-3,122 Reduced 1.34%
230,520 $502 Million
Q2 2020

Aug 30, 2024

BUY
$1.58 - $2.86 $18,912 - $34,234
11,970 Added 5.4%
233,642 $467 Million
Q1 2020

Aug 30, 2024

SELL
$1.43 - $3.23 $56,763 - $128,214
-39,695 Reduced 15.19%
221,672 $347 Million
Q4 2019

Aug 30, 2024

BUY
$2.74 - $4.2 $716,145 - $1.1 Million
261,367 New
261,367 $847 Million

Others Institutions Holding THTX

# of Institutions
1
Shares Held
29.2K
Call Options Held
0
Put Options Held
0

About Theratechnologies Inc.


  • Ticker THTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,141,600
  • Market Cap $155M
  • Description
  • Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with l...
More about THTX
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.